{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076018","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.484027+00:00","generated_at":"2026-05-17T12:51:52.167736+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue","bullets":["Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024","Shareholders' equity rose to $9.5 million from $8.0 million year-over-year","Diluted loss per share improved to $(0.13) from $(0.42) full-year 2024 loss","Acquired farmland in Taiwan valued at approximately $3.3 million for R&D and GMP expansion","Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076018","json":"https://secwatch.observer/filing/0001213900-25-076018.json","markdown":"https://secwatch.observer/filing/0001213900-25-076018.md","text":"https://secwatch.observer/filing/0001213900-25-076018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025076018/0001213900-25-076018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025076018/ea0253086-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T12:51:52.167736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}